Recent evidences suggest that these compounds also protect against obesity and co-morbities [230]; their anti-adipogenic and anti-lipogenic effects may be due to the ability of estrogen receptors to interact with PPAR, thus modulating adipose development, insulin sensitivity and fatty acid metabolism. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.